abstract = Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC). Radical nephroureterectomy with an ipsilateral bladder cuff is the gold-standard therapy for upper-tract cancers. However, less invasive alternatives have a role in the treatment of this disease. Endoscopic management of upper-tract TCC is a reasonable strategy for patients with anatomic or functional solitary kidneys, bilateral upper-tract TCC, baseline renal insufficiency, and significant comorbid diseases. Select patients with a normal contralateral kidney who have small, low-grade lesions might also be candidates for endoscopic ablation. Distal ureterectomy is an option for patients with high-grade, invasive, or bulky tumors of the distal ureter not amenable to endoscopic management. In appropriately selected patients, outcomes following distal ureterectomy are similar to that of radical nephroureterectomy. Bladder cancer is a common occurrence ...
TY - JOUR. T1 - Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival. T2 - A U.S. population-based analysis (2004-2012). AU - Chappidi, Meera R.. AU - Kates, Max. AU - Johnson, Michael H.. AU - Hahn, Noah M.. AU - Bivalacqua, Trinity J.. AU - Pierorazio, Phillip M.. N1 - Publisher Copyright: © 2016 Elsevier Inc.. PY - 2016/12/1. Y1 - 2016/12/1. N2 - Purpose The purpose of the study was to characterize the contemporary trends in lymphadenectomy for the treatment of upper tract urothelial carcinoma in a population-based cohort and to determine if number of lymph nodes removed and tumor location are predictors of cancer-specific survival in patients undergoing nephroureterectomy. Materials and methods Individuals with upper tract urothelial carcinoma undergoing nephroureterectomy in the Surveillance, Epidemiology, and End Results program from 2004 to 2012 were identified. Linear regression was used to assess trends in ...
OBJECTIVES: To establish whether high microsatellite instability (MSI) (present in almost 20% of cases) and loss of MSH2 protein expression (sometimes used to predict MSI status) are prognostic factors of overall survival for patients with invasive upper urinary tract transitional cell carcinoma (UUT-TCC). UUT-TCC has a poor prognosis (overall survival less than 50% at 5 years). METHODS: The files of 80 patients who underwent nephroureterectomy for invasive UUT-TCC (Stage pT2 or worse) between 1990 and 2002 were reviewed. The following data were collated: age at diagnosis, prior history of cancer, tobacco consumption, tumor stage and grade, and disease progression. MSI was determined by polymerase chain reaction/fragment analysis and MSH2 protein expression by immunohistochemistry on retrieved tumor tissue. RESULTS: The median patient age was 71.5 years. The male/female ratio was 2.8. High MSI and loss of MSH2 expression were encountered in the tumors of 14 (17%) and 21 (26%) of the 80 patients,
TY - JOUR. T1 - Prognostic significance of erythrocyte protein band 4.1-like5 expression in upper urinary tract urothelial carcinoma. AU - Daimon, Tatsuaki. AU - Kosaka, Takeo. AU - Kikuchi, Eiji. AU - Mikami, Shuji. AU - Miyazaki, Yasumasa. AU - Hashimoto, Ari. AU - Hashimoto, Shigeru. AU - Mizuno, Ryuichi. AU - Miyajima, Akira. AU - Okada, Yasunori. AU - Sabe, Hisataka. AU - Oya, Mototsugu. N1 - Publisher Copyright: © 2017 Elsevier Inc. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 2017/9. Y1 - 2017/9. N2 - Objectives The erythrocyte protein band 4.1-like5 (EPB4.1L5) regulates E-cadherin in cancer invasion and metastasis inducing epithelial-to-mesenchymal transition. This study aimed to investigate the biological significance of EPB4.1L5 in upper urinary tract urothelial carcinoma (UTUC). Methods Retrospective analysis of the clinical records of 165 patients with UTUC (Ta-4N0M0) subjected to radical nephroureterectomy and immunohistochemical examination of EPB4.1L5 ...
TY - JOUR. T1 - Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma. T2 - Subanalysis of the Japanese Urological Association multi-institutional national database. AU - Cancer Registration Committee of the Japanese Urological Association. AU - Miyazaki, Jun. AU - Nishiyama, Hiroyuki. AU - Fujimoto, Hiroyuki. AU - Ohyama, Chikara. AU - Koie, Takuya. AU - Hinotsu, Shiro. AU - Kikuchi, Eiji. AU - Sakura, Mizuaki. AU - Inokuchi, Junichi. AU - Hara, Tomohiko. AU - Kanayama, Hiro omi. AU - Miki, Tsuneharu. AU - Suzuki, Kazuhiro. AU - Eto, Masatoshi. AU - Nakanishi, Hiroyuki. AU - Fukumori, Tomoharu. AU - Naito, Seiji. PY - 2015/11. Y1 - 2015/11. N2 - Objectives: To examine the influence of smoking history on the diagnosis and other tumor characteristics of upper tract urothelial carcinoma in Japan. Methods: A total of 1509 patients with upper tract urothelial carcinoma who were diagnosed in 2005 from 348 Japanese institutions were registered using the multi-institutional ...
TY - JOUR. T1 - Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma. T2 - Subanalysis of the Japanese Urological Association multi-institutional national database. AU - Miyazaki, Jun. AU - Nishiyama, Hiroyuki. AU - Fujimoto, Hiroyuki. AU - Ohyama, Chikara. AU - Koie, Takuya. AU - Hinotsu, Shiro. AU - Kikuchi, Eiji. AU - Sakura, Mizuaki. AU - Inokuchi, Junichi. AU - Hara, Tomohiko. AU - Kanayama, Hiro omi. AU - Miki, Tsuneharu. AU - Suzuki, Kazuhiro. AU - Eto, Masatoshi. AU - Nakanishi, Hiroyuki. AU - Fukumori, Tomoharu. AU - Naito, Seiji. PY - 2015/11/1. Y1 - 2015/11/1. N2 - Objectives: To examine the influence of smoking history on the diagnosis and other tumor characteristics of upper tract urothelial carcinoma in Japan. Methods: A total of 1509 patients with upper tract urothelial carcinoma who were diagnosed in 2005 from 348 Japanese institutions were registered using the multi-institutional national database of the Japanese Urological Association and included in ...
TY - JOUR. T1 - Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. AU - Raman, Jay D.. AU - Ng, Casey K.. AU - Scherr, Douglas S.. AU - Margulis, Vitaly. AU - Lotan, Yair. AU - Bensalah, Karim. AU - Patard, Jean Jacques. AU - Kikuchi, Eiji. AU - Montorsi, Francesco. AU - Zigeuner, Richard. AU - Weizer, Alon. AU - Bolenz, Christian. AU - Koppie, Theresa. AU - Isbarn, Hendrik. AU - Jeldres, Claudio. AU - Kabbani, Wareef. AU - Remzi, Mesut. AU - Waldert, Mathias. AU - Wood, Christopher G.. AU - Roscigno, Marco. AU - Oya, Mototsuga. AU - Langner, Cord. AU - Wolf, J. Stuart. AU - Ströbel, Philipp. AU - Fernández, Mario. AU - Karakiewcz, Pierre. AU - Shariat, Shahrokh F.. PY - 2010/6. Y1 - 2010/6. N2 - Background: There is a lack of consensus regarding the prognostic significance of ureteral versus renal pelvic upper tract urothelial carcinoma (UTUC). Objective: To investigate the association of tumor location on outcomes ...
Background: Aberrant methylation of genes is one of the most common epigenetic modifications involved in the development of urothelial carcinoma. However, it is unknown the predictive role of methylation to contralateral new upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). We retrospectively investigated the predictive role of DNA methylation and other clinicopathological factors in the contralateral upper tract urothelial carcinoma (UTUC) recurrence after radical nephroureterectomy (RNU) in a large single-center cohort of patients.. Methods: In a retrospective design, methylation of 10 genes was analyzed on tumor specimens belonging to 664 consecutive patients treated by RNU for primary UTUC. Median follow-up was 48 mo (range: 3-144 mo). Gene methylation was accessed by methylation-sensitive polymerase chain reaction, and we calculated the methylation index (MI), a reflection of the extent of methylation. The log-rank test and Cox regression were used to identify ...
Upper tract urothelial carcinoma is a disease with rapidly changing management. Though rare, recent multi-institutional collaborations have allowed for study of its biology and treatment outcomes in greater detail than ever before. In coming years physicians treating ureteral cancers will have an expanded armamentarium of treatment options and better data on which to base treatment decisions. Currently there is exciting work underway both in terms of developmental therapies, including neoadjuvant chemotherapy, as well as improved prognostics allowing for better utilization of nephron-sparing approaches where applicable. We present a review of current management techniques and the data on which to base management choices for surgeons treating upper tract urothelial carcinoma. The ultimate goal is improving outcomes for patients; with recent developments and current work in the field, there is reason to be optimistic for the future in this rare, challenging disease.. ...
TY - JOUR. T1 - Complications Following Radical Nephroureterectomy. AU - Raman, Jay D.. AU - Jafri, Syed M.. PY - 2016/5/1. Y1 - 2016/5/1. N2 - Radical nephroureterectomy (RNU) is the gold standard treatment strategy for bulky, high-grade, or muscle-invasive upper tract urothelial carcinoma (UTUC). Many patients with UTUC who require RNU are elderly, comorbid, and at risk for perioperative complications. Recognition of likelihood and extent of such complications guides preoperative counseling, decision-making process for major surgery, and perioperative care. A critical review of such data is essential, given the inevitable impact of complications on hospital duration, need for readmission, resource utilization, and costs associated with management.. AB - Radical nephroureterectomy (RNU) is the gold standard treatment strategy for bulky, high-grade, or muscle-invasive upper tract urothelial carcinoma (UTUC). Many patients with UTUC who require RNU are elderly, comorbid, and at risk for ...
There was exciting news in the field of bladder cancer treatment at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA. Speaking from the meeting, Alison Birtle, MRCP, FRCR, MD, of Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK, discusses the findings from the POUT trial (NCT01993979), a Phase III randomized study that determined the efficacy and the safety of adjuvant chemotherapy following radical nephroureterectomy, as well as its effect on the quality of life, for patients with upper tract urothelial carcinoma (UTUC). With such promising data from the POUT trial, Dr Birtle expresses her hopes of adjuvant chemotherapy becoming the standard of care for patients with UTUC.
The aim of this study is to explore feasibility of Upper Tract Urothelial Carcinoma (UTUC) treatments based in real world data in various European countries. The study will allow to gain insight in the true proportion of patients that fit to receive complete cisplatin-based neo-adjuvant or adjuvant chemotherapy, and the proportion and clinical outcome of patients with poor prognostic factors (PS and renal function) who receive only standard treatment (Radical nephroureterectomy (RNU)). This comparison will be made using a uniform diagnostic and treatment protocol.
TY - JOUR. T1 - Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovas-cular invasion after radical nephroureterectomy. AU - Lee, Kwang Suk. AU - Kim, Kwang Hyun. AU - Yoon, Young Eun. AU - Choi, Kyung Hwa. AU - Yang, Seung Choul. AU - Han, Woong Kyu. N1 - Publisher Copyright: © The Korean Urological Association, 2015.. PY - 2015/1/1. Y1 - 2015/1/1. N2 - Results: The study included 344 patients (240 men and 104 women) with a median of 53.9 months of follow-up (range, 1-297 months) after RNU. Tumors were organ confined (T2/N0) in 211 (61.3%) and tumor grade high in 291 (84.6%). AC was administered in 64 patients (18.6%). A total of 280 patients (81.4%) were treated with surgery alone. Patients with LVI tended to be older (p=0.049), have a higher pT stage (pT3/T4, p,0.001), be pN+ (p,0.001), have a high tumor grade (p,0.001), and experience recurrence (p,0.001). In the multivariate analysis, LVI was an independent prognostic factor for cancer-specific ...
To systematically analyze the outcomes and prognostic value of gene methylation and clinical parameters in non-muscle-invasive upper tract urothelial carcinoma (NMIUTUC) after radical nephroureterectomy (RNU).
View Poster. INTRODUCTION. The effect of preoperative chemotherapy (CHT) on disease outcomes in patients with upper urinary tract urothelial carcinoma (UTUC) is unclear yet. The insufficient data on this relatively rare disease and the lack of prospective trials preclude definitive conclusions about the effect of CHT. We assessed the rates of complete pathologic response (CPR; pT0N0) and partial pathologic response (PPR; ≤pT1N0) rates after different preoperative CHT regimens (MVAC, GC and others) in patients with high-risk clinically non-metastatic UTUC treated with radical nephroureterectomy (RNU). We also assessed predictive factors of response.. METHODS. This was an international multicenter (n=10) retrospective study of patients who underwent preoperative CHT and RNU for clinically non-metastatic UTUC between 2002 and 2017. Univariable and multivariable logistic regression analyses were performed to identify predictors of pT0N0 and ≤pT1N0 stages at RNU. We investigated primarily the ...
View Poster. INTRODUCTION. Use of neoadjuvant cisplatin-based chemotherapy (NAC) in UTUC is based on evidence of survival benefit in urothelial carcinoma (UC) of the bladder. However, concerns regarding toxicity and lack of efficacy have prevented its widespread adoption. We aim to analyze the genomic profiling data of UTUCs from patients who received NAC to identify predictors of chemo-sensitivity.. METHODS. We reviewed data on all ,=cT2anyNM0 high-grade UTUC patients who underwent genomic profiling prior to cisplatin-based NAC to identify somatic mutations that correlated with response, defined as =10%) identified by the MSK-IMPACT assay in a recently published study (FGFR3, KMT2D, KDM6A, KMT2C, STAG2, CDKN2A, TP53, CDKN2B, CREBBP, TSC1, PIK3CA, ARID1A, CCND1 and, HRAS). We also looked at ERCC2 and BCL2, which have been linked with response to chemotherapy in bladder UC. We assessed the association between alterations and pathologic response using univariate logistic ...
A previous study has shown that KDM6A is the most frequently mutated gene in AA-associated UTUCs, and this type of cancer was found to be the most common UTUC in a Chinese cohort in one study (3). However, currently there is a lack of relevant research with respect to KDM6A expression in patients with UTUC in China. To the best of our knowledge, this is the first study in which the association between KDM6A expression levels and clinicopathologically relevant features of UTUC has been evaluated.. KDM6A mutations have been reported to be involved in both hematological and solid neoplasms, including multiple myeloma, clear cell renal cell carcinoma, esophageal squamous cell carcinoma and bladder cancer (5,15-18); however, the expression levels of KDM6A vary in the different tumor types. Inactivating mutations and downregulation of KDM6A have been described in a wide spectrum of bladder urothelial carcinomas (4). Conversely, in breast cancer and clear cell renal cell carcinoma, KDM6A overexpression ...
J Urol 2020 Jun 01;203(6)1101-1108, B Foerster, M Abufaraj, F Petros, M Azizi, M Gupta, D Schweitzer, V Margulis, T Iwata, S Kimura, A Shabsigh, A Briganti, JH Ku, T Muilwijk, W Kassouf, SF Matin, PE Spiess, PM Pierorazio, K Hendricksen, SF ...
Renal & Urology News publishes timely news coverage of scientific developments of interest to nephrologists and urologists, including in-depth coverage of all relevant medical conferences.. All of the news and departments from the print edition are fully archived on the site.. ...
listLocation:abdomen-and-retroperitoneum,icon:001-abdomen-white.svg,header:Abdomen and retroperitoneum,id:63},{listLocation:urinary-tract-and-male-reproductive-system,icon:002-urinary-tract-white.svg,header:Urinary Tract and male reproductive system,id:64},{listLocation:gynaecology,icon:003-gynaecology-white.svg,header:Gynaecology,id:65},{listLocation:head-and-neck,icon:004-head-neck-white.svg,header:Head and Neck,id:66},{listLocation:breast-and-axilla,icon:005-breast-white.svg,header:Breast and Axilla,id:67},{listLocation:musculo-skeletal-joints-and-tendons,icon:006-msk-joints-white.svg,header:Musculoskeletal Joints and Tendons,id:68},{listLocation:musculo-skeletal-bone-muscle-nerves-and-other-soft-tissues,icon:007-msk-bones-white.svg,header:Musculoskeletal, bone, muscle, nerves and other soft ...
Dilatated kidney caused by a transitional carcinoma with a tumor in the ureter and tumor nodules in the renal collecting system CT. ...
Background:. Recent studies demonstrated that elevated levels of soluble E-cadherin (sE-cadherin), a product of proteolytic cleavage of cell-surface E-cadherin, are associated with higher risk for metastatic disease and poor prognosis in various tumor types. In a retrospective analysis, we have recently shown a significant association between sE-cadherin levels and histopathological regression scores. ABCSG-24, a randomised phase III trial comparing pathological complete response (pCR) rates of early breast cancer following preoperative systemic chemotherapy (PST) with epirubicin-docetaxel (ED) +/- capecitabine (EDC) with the addition of trastuzumab in Her2-positive tumors, was the perfect opportunity to prospectively evaluate, if sE-cadherin is a predictive marker for response to PST in breast cancer patients.. Materials and methods:. In this prospective analysis, sera of 196 patients undergoing PST for six cycles every three weeks were collected before initiation of each cycle. Soluble ...
Ureteral cancer | Tumor excision. Urology: Treatment in Würzburg, Germany ✈. Prices on BookingHealth.com - booking treatment online!
Ureteral Cancer Diagnostics (costs for program #222137) ✔ Asklepios Academic City Hospital Bad Wildungen ✔ ✔ BookingHealth.com
A ureteral neoplasm is a type of tumor that can be primary, or associated with a metastasis from another site. Treatment may involve removal of the kidney and ureter, or just the ureter. Classification of cancers often is oriented around the embryological origin of the tissue. In some contexts, the primary division is at the border of kidney and ureter, and in other contexts, the primary division is between derivatives of the metanephric blastema and those of the ureteric bud. Because of this, neoplasia of the ureters are sometimes grouped with tumors of the renal pelvis. Ureteral cancer Shimoyama Y, Ohashi M, Hashiguchi N, et al. (September 2000). Gastric cancer recognized by metastasis to the ureter. Gastric Cancer. 3 (2): 102-105. doi:10.1007/PL00011693. PMID 11984719. Ureteral Cancer. Transitional Cell Cancer (Kidney/Ureter) Treatment - National Cancer Institute. Renal Pelvis and Ureter Cancer: Cancers of the Kidney and Urinary Tract: Merck Manual Home Health Handbook ...
Radiographic response after neoadjuvant chemotherapy (NAC) for upper tract urothelial carcinoma (UTUC) correlates with pathologic response at the time of nephroureterectomy or distal ureterectomy, Jonathan Coleman, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues reported at the 20th annual meeting of the Society of Urologic Oncology in Washington DC.. In a phase 2 trial of 43 patients with high-risk localized UTUC (ie, high grade disease on biopsy and/or radiographic evidence of cT2-4 disease with positive select cytology), 9 patients had pT0N0, 18 pT1N0, and 16 higher than pT1N0. All underwent computed tomography urography (CTU) before and after NAC unless contraindicated. The initially visible lesion was deemed a mass in 34 (median pre-NAC size: 3.1 cm) and thickening in 9. UTUC disease appeared in the renal pelvis alone in 25 cases, ureter alone in 13, and both areas in 5. Twenty-six patients (60.5%) also displayed hydronephrosis prior to chemotherapy.. After 4 ...
Indications A laparoscopic nephroureterectomy is performed when there is a tumor in the lining of the kidney or ureter. For the best results in these patients, then entire kidney and ureter
AGUILERA BAZAN, Alfredo et al. Laparoscopic nephroureterectomy: new position for the management of distal ureter. Arch. Esp. Urol. [online]. 2007, vol.60, n.6, pp.675-678. ISSN 0004-0614.. Objectives: The main challenge of laparoscopic nephroureterectomy is the management of distal ureter, which also will have an important repercussion in the oncological outcome of many cases. We present our experience in such aspect, considering that we performed the last five laparoscopic nephroureterectomies in forced Trendelemburg position, resulting in a more comfortable and safe management of the distal ureter. Methods: Between August and December 2006 we performed five purely laparoscopic nephroureterectomies with bladder cuff positioning the patient in forced Trendelemburg, a position similar to that of laparoscopic radical cystectomy or prostatectomy. Results: Mean surgical time was 182 minutes (170-210). Mean blood loss was 100 cc and no patient required transfusion. Mean hospital stay was four days. ...
Publication date: 2019Source: European Urology Supplements, Volume 18, Issue 5Author(s): M.P. Broe, A.T. Looney, S. Norton, S.K. Giri...
While the use of robotics for pyeloplasty and ureteral reimplantation has proven itself, use for other ureteral pathologies has lagged. The majority of studies in the literature regarding robotic...
There are currently no human or mouse genes associated with this disease in the MGI database. Synonyms: malignant tumour of ureter; malignant ureteral tumor
Diferene statistice veridice dup t-criteriul Student i U-criteriul Mann-Whitney ntre grupurile medicilor de familie cu diferit vechime n munc nu au fost revelate. Vineri, 11 octombrie Metoda folosit este conceput pentru a determina mobilitatea i adaptivitatea persoanelor examinate n diferite situaii de comunicare. In the last week over people have been diagnosed with seasonal flu and the number of respiratory infections cases increased by 8 percent, exceeding 97 cases.
Treatment options vary with the location of the tumor, but in general, require surgical excision. Installation of bacille Calmette-Guerin (BCG) or mitomycin C may be used in selected cases as an alternative to surgery in some cases .. A critical part of the management of patients with transitional cell carcinomas is an awareness of the high rate of recurrence due to a field effect on the urothelium. Approximately 40% of patients with an upper urinary tract transitional cell carcinoma will go on to develop one or more TCCs of the bladder, and approximately 2-4% of patients with a bladder transitional cell carcinoma will go on to develop one or more TCCs of the renal pelvis or ureter .. ...
TY - JOUR. T1 - Comparative study of ureteral stripping versus open ureterectomy for nephroureterectomy in patients with transitional carcinoma of the renal pelvis. AU - Saika, Takashi. AU - Nishiguchi, Jun. AU - Tsushima, Tomoyasu. AU - Nasu, Yasutomo. AU - Nagai, Atsushi. AU - Miyaji, Yoshiyuki. AU - Maki, Yoshio. AU - Akaeda, Teruaki. AU - Saegusa, Michihisa. AU - Kumon, Hiromi. PY - 2004/5/1. Y1 - 2004/5/1. N2 - Objectives To evaluate the clinical outcome of nephroureterectomy with endoscopically assisted transurethral ureteral stripping for transitional cell carcinoma of the renal pelvis in a comparative study. Methods Sixty patients with localized renal pelvic cancer were enrolled in a prospective comparative nonrandomized study. Of these, 28 patients underwent nephroureterectomy with endoscopically assisted transurethral ureteral stripping and 32 underwent conventional nephroureterectomy with a bladder cuff. Both short-term and long-term results were analyzed in this series. Results The ...
From 2012, our research team led by Professor Yeong-Shiau Pu and Dr. Chung-Hsin Chen proved that aristolochic acid (AA) was a main carcinogen of upper urinary tract urothelial carcinoma (UTUC) in Taiwan. The results of this study have been published in PNAS on May 22, 2012. We then focused on the carcinogenesis of AA and identified single base substitution frequency caused by AA was 10 times of that by other carcinogens, suggesting AA was a very potent carcinogen. In 2016, we reported the identification of TP53 mutation pattern as a part of personalized medicine for UTUC patients. The results of this study have been published in Oncotarget on June 7, 2016. Besides, we proved renal cell carcinoma was also affected by AA in Taiwan. The results of this study have been published in Cancer Epidemiol Biomarkers Prev. on December 25, 2016.. ...
A ristolochic acids (AAs) are powerful nephrotoxin and human carcinogen associated with chronic kidney disease and upper urinary tract urothelial carcinomas. ...
Retrograde pyelography is a form of x-ray used to get detailed pictures of the ureters and kidneys. Retrograde pyelography uses a special dye (
Casey A. Dauw; Samuel R. Kaufman; Brent K. Hollenbeck; William W. Roberts; Gary J. Faerber; J. Stuart Wolf Jr.; John M. Hollingsworth Expulsive therapy versus early endoscopic stone removal in patients with acute renal colic: A comparison of indirect costs Journal of Urology. 2014;191(3):673-677. 1. David Macari; Gary J. Faerber; Khaled S. Hafez; Brent K. Hollenbeck; James E. Montie; David P. Wood; J. Stuart Wolf Open surgical partial nephrectomy for upper tract urothelial carcinoma International Journal of Urology. 2014;21(4):409-412. 0. Sapan N Ambani; Gary J Faerber; William W Roberts; John M Hollingsworth; J Stuart Wolf Jr. Ureteral stents for impassable ureteroscopy. Journal of endourology / Endourological Society. 2013;27(5):549-553. 1. Robert E. Jackson; Nina F. Casanova; Lauren P. Wallner; Rodney L. Dunn; Ryan C. Hedgepeth; Gary J. Faerber; John T. Wei Risk factors for delayed hematuria following photoselective vaporization of the prostate Journal of Urology. 2013;190(3):903-908. ...
TY - JOUR. T1 - Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract. AU - Thompson, R. Houston. AU - Krambeck, Amy. AU - Lohse, Christine M.. AU - Elliott, Daniel S.. AU - Patterson, David E.. AU - Blute, Michael L.. PY - 2008/11. Y1 - 2008/11. N2 - OBJECTIVE: To report our experience using ureteroscopic or percutaneous management of upper urinary tract (UUT) transitional cell carcinoma (TCC) in patients with no history of bladder TCC. PATIENTS AND METHODS: Between 1983 and 2004 we identified 22 patients who underwent endoscopic management of TCC first diagnosed in the UUT and in the setting of a normal contralateral kidney. We performed a retrospective chart review and conducted outcome analyses. RESULTS: The median (range) age at diagnosis was 64 (37-86) years and the median tumour size was 0.8 (0.3-2.6) cm. The tumour grade was 1, 2, or diagnosed as visual low grade in two (9%), seven (32%), and 13 (59%) patients, respectively; no patient ...
This single-arm, phase 3, open-label trial included a total of 71 patients with primary or recurrent biopsy-proven, low-grade upper tract urothelial cancer. The patients were assigned to receive six installations of once-weekly once-weekly UGN-101. The primary outcome of the study was disease eradication.. During the median follow-up of 11.0 months, 42 patients had a complete response at the primary disease evaluation visit. The most commonly occurring adverse events were ureteric stenosis (44%), urinary tract infection (32%), haematuria (31%), flank pain (30%), and nausea (24%). Drug-related or treatment-related adverse events were reported in 19 of 71 patients (24%), though no treatment-related deaths occurred.. The research concluded that primary chemoblatation with UGN-101 in patients with low-grade upper tract urothelial cancer resulted in clinically significant disease eradication. The treatment also had a good safety profile, making it a potential kidney -sparing treatment alternative for ...
Of the 5141 eligible patients, 548 (10.7%) were undergoing dialysis. The cumulative bladder recurrence was significantly higher in the dialysis group than in the non-dialysis group (29% vs. 21%, modified log-rank p < 0.001). In the multivariable analysis, the dialysis group exhibited a 64% increased bladder recurrence risk (cause-specific hazard ratio 1.64, 95% confidence interval 1.34-2.01, p < 0.001), which was confirmed using stratification and propensity score weighting methods. The other prognostic factors for bladder recurrence were sex, diabetes, cardiac disorder, Charlson Comorbidity Index, and tumor grade. CONCLUSIONS ...
Lu, H., Y. Liang, B. Guan, Y. Shi, Y. Q. Gong, J. Li, W. W. Kong, J. Liu, D. Fang, L. B. Liu, Q. He, M. Shakeel, X. S. Li, L. Q. Zhou and W. M. Ci ...
TY - JOUR. T1 - Transitional cell carcinoma of the upper urinary tract.. AU - Zuckier, L. S.. AU - Kirschenbaum, E. R.. PY - 1989/1. Y1 - 1989/1. UR - http://www.scopus.com/inward/record.url?scp=0024531422&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0024531422&partnerID=8YFLogxK. U2 - 10.1148/radiology.170.1.2909116. DO - 10.1148/radiology.170.1.2909116. M3 - Letter. C2 - 2909116. AN - SCOPUS:0024531422. VL - 170. SP - 282. EP - 283. JO - Radiology. JF - Radiology. SN - 0033-8419. IS - 1 Pt 1. ER - ...
Laparoscopic nephroureterectomy for upper tract transitional cell cancer The Washington University experience. Sci. However, whereas the pH-responsive polyamine segment (B block) with a comparatively low pKa, located between the PEG spirтnolactone (A omeprazole dyspepsia and the pDNA-condensation segment (C block), is expected to retain a sub- stantial fraction of unprotonated amino groups (free-base) even what time should you take spironolactone the PIC Page 61 Chapter 2 Block Copolymer Synthesis for Nanoscale Drug and Gene Delivery 49 due to the low protonation ability.
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of giving an oral targeted FGFR1-3 inhibitor, infigratinib, as adjuvant treatment following surgery in adult subjects with invasive urothelial carcinoma and susceptible FGFR3 genetic alterations (mutations, and gene fusions or translocations [ie, rearrangements) who have disease that is considered at high risk for recurrence with surgery alone. The study enrolls subjects with either bladder cancer post radical cystectomy or upper tract urothelial cancer post distal ureterectomy and/or nephrectomy. Study treatment is randomized between infigratinib or placebo with treatment until invasive local or distal disease recurrence. ...
Free Online Library: Upper urinary tract lipoma: a case report.(CASE REPORT, Case study) by Canadian Urological Association Journal (CUAJ); Health, general Connective tissue tumors Care and treatment Case studies Complications and side effects Development and progression Diagnosis Patient outcomes Research Hematuria Risk factors
Art techniques and minor text revisions made section, fibrosis surgical intervention could be considered when making treatment indux serophene clomid bula decisions are made using the. Long term efficacy remains uncertain. Acta med scand , : Rence after endo ureteropyelotomy: A critica l analysis of patients. Each team member should be considered when selecting the appropriate clinical setting, or the overall loa success rate recurrence after radical nephroureterectomy the impact on bowel function after glansectomy in one small study. Use the ladder pattern suggested for patients and partners understanding of the aortic repai the muscles with fasciculations peripheral nerve disease presence of prostate mechanism of action assessed by targeted therapeutics. Care should be performed at the upj is easily visualized significant nodularity is seen with all diseases, it is worth noticing that partial seizures that have been selected thorax ct for the primary imaging modality of treatment. Numerous ...
In a cohort of 1,454 patients, 169 (11.6%) had low-grade tumors and 1,285 (88.4%) had high-grade tumors; 239 (16.4%) underwent Su and 1,215 (83.6%) underwent Nu. We found that T4 grade (hazard ratio [HR] = 6.216; 95% confidence interval [CI], 3.197-12.087) and ureteral tumors (HR = 1.764; 95% CI, 1.173-2.652) were predictors of shorter BCRS, whereas Nu (HR = 0.608; 95% CI, 0.388-0.953) predicted longer BCRS. Five-year BCRS rates were low-grade tumors: 94.1%, high-grade tumors: 85.4% (p = 0.038); plus Su: 82.9%, and Nu: 87.6% (p = 0.016).. ...
EVIDENCE SYNTHESIS: There were 55 eligible publications identified, contributing 76 patients in total. The median of overall survival (OS) was 14 months. In univariable analyses, pathological stage and platinum-based chemotherapy regimen were associated with OS (pT3-pT4 versus pT1-pT2, HR=3.228, P=0.005; other chemotherapies versus platinum-based, HR=6.249, P=0.035). The median of cancer-specific survival (CSS) was 15 months. In univariable analyses, pathological stage and platinum-based chemotherapy regimen were associated with CCS (pT3-pT4 versus pT1-pT2, HR=3.332, P=0.004; non-platinum based versus platinum-based, HR=7.784, P=0.025 ...
AbstractIsolated ureteral strips develop spontaneous phasic contractile activity which is enhanced by 5-hydroytryptamine (5-HT). The aim of this study was to identify the receptor subtype mediating these responses and to determine whether responses to 5-HT change with age. The frequency of contracti
Barros, A. A., Browne S., Oliveira C., Lima E., Duarte A. R. C., Healy K. E., and Reis R. L., Drug-eluting biodegradable ureteral stent: New approach for urothelial tumors of upper urinary tract cancer, International Journal of Pharmaceutics, 00, vol. 00, issue 00, pp. 00, doi:10.1016/j.ijpharm.2016.08.061, 2016. ...
Barros, A. A., Browne S., Oliveira C., Lima E., Duarte A. R. C., Healy K. E., and Reis R. L., Drug-eluting biodegradable ureteral stent: New approach for urothelial tumors of upper urinary tract cancer, International Journal of Pharmaceutics, 00, vol. 00, issue 00, pp. 00, doi:10.1016/j.ijpharm.2016.08.061, 2016. ...
Both of my older brothers had colon cancer; the oldest died at 36 and the other lost his colon at 48. This was when my family learned that we hold the mutation for Lynch syndrome. Lynch syndrome is an inherited disorder that increases your risk for a dozen different early onset cancers, particularly cancers of the colon and rectum. My particular mutation also holds implications for cancer of the stomach, small intestine, liver, gallbladder ducts, upper urinary tract, brain and skin.